Biotech Bucks Bearish Market Trend
By Bill Luby on July 30, 2008 | More Posts By Bill Luby | Author's Website
While most sectors have been faltering for the past month or two, biotechnology has been an exceptional performer, with the top biotech ETF, (IBB), now more than 15% above its June low, as the chart below shows.
I last profiled biotech on May 1st in Time for Biotech to Turn Around? In retrospect, May and June were excellent months to get long biotech, even as the broad markets headed south.
Of IBBs top ten holdings, five of the ten are currently at or just below their 52 week highs, including:
- Amgen (AMGN) – making another new 52 week high today
- Illumina (ILMN) – made a new 52 week high yesterday
- Celgene (CELG) – just 1.6% below its 52 week high
- Gilead Sciences (GILD) – 5.7% below its 52 week high, but up about 40% for the year
- Genzyme [GENZ]] – 7.1% below the 52 week high, set back in January
Of course, there are many more success stories among some of the smaller cap biotechnology companies. So while the markets drift sideways and we wait to see if traditional technology stocks can provide leadership, this might be a good time to stock up on one of the few strong sectors: biotechnology.

Australian Dollar: The Downside Prevails
Canadian Dollar: Caution
Health Care Reform Or Merely Another Wealth Redistribution Program?
US Bank Failure Tally Hits 120 So Far This Year
There Remains Little Obstacle On The Horizon To Halt The US Dollar Sell-Off
Stocks Posting Strong Gains In Mid-Morning Trading - U.S. Commentary - 27 mins ago
Stocks See Initial Strength, Dow Climbs Back Near One-Year High - U.S. Commentary - 1 hr ago
Latvia Trade Deficit Narrows In September - 1 hr ago
Latvia Consumer Prices Decline For First Time Since 1991 - 1 hr ago
Latvia’s Economy Contracts 18.4% In Q3 - 1 hr ago


